In order to better understand the impact of “Lifestyle Therapy” on diabetes treatment and patient outcomes, a comprehensive longitudinal cohort study is being jointly developed by Kantar Health, a global leader in healthcare consulting and market research, and Nokia, an innovator of technologies at the heart of our connected world. The novel combination of biometric and longitudinal, real-world data will drive better consumer insights through a holistic, 360-degree view of the diabetes patient, enabling healthcare companies to make better decisions for managing and treating this globally advancing chronic disease.
“As the role of the patient continues to evolve, management of chronic conditions such as diabetes is transforming through the ever increasing use of connected devices in patient populations,” said Geneviève Bonnelye, Managing Director, Kantar Health. “Lifestyle therapy, including changes in nutrition, physical activity, sleep and nicotine use, is an essential component of type 2 diabetes treatment, however there’s a lack of longitudinal patient data about the disease’s impact on weight, activity level, sleep and blood pressure, as well as limited evidence on how treatment management is affecting patients’ loss or gain of weight. There’s a clear need for a solution that combines attitudinal and evidence-based data, helps manage weight and links treatment management and HBA1C results. Our landmark study with Nokia should help fill these data gaps and ultimately improve patient care.”
“The global healthcare community must continue to cultivate data-based consumer insights to form a more complete picture of the modern patient,” said Cedric Hutchings, Vice President of Digital Health, Nokia, which now features the award-winning Withings line of connected health products – including connected activity trackers, smart scales, wireless blood pressure monitors and temporal thermometers. “Nokia’s continued efforts to better understand patient-generated health data supports our vision to better equip individuals to take control of their own health.”
Kantar Health will contribute the real-world study design and execution expertise to the project, while Nokia will leverage its world-class technology assets to generate biometric data and facilitate study delivery. The first data analysis of research findings is expected by the Fall of 2017. Final research findings will be completed and announced by the Spring of 2018. Data from the research will be made available to the industry for purchase.
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 600+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit www.kantarhealth.com.
+1 215 820 6621